A study presented at the 47th Society of Gynecologic Oncology meeting held in San Diego, found that women with ovarian cancer who received statin therapy in tandem with their cancer treatment had better survival.
A study presented at the 47th Society of Gynecologic Oncology meeting held in San Diego, found that women with ovarian cancer who received statin therapy in tandem with their cancer treatment had better survival.
An analysis of Medicare claims data, found that statin use resulted in a 34% reduction in survival hazard among 1510 Medicare-age women (P < .0001), specifically in those who were treated with lipophilic statin agents. At moderate to high doses.
For this study, the authors used Medicare-linked data from the National Cancer Institute Surveillance, Epidemiology, and End Results program for newly diagnosed epithelial ovarian cancer during 2007 to 2009. Statin use was defined by an existing prescription at the time of surgery or a new prescription after surgery. The data showed that 636 of the 1,510 patients qualified as statin users during the study period. The statin of choice was a lipophilic agent in 88.7% of cases -- atorvastatin (Lipitor), lovastatin (Mevacor), or simvastatin (Zocor). Dosage was moderate in 70.4% of statin users and high in 15.3%.
According to the report in Medpage Today, statin users had a median overall survival (OS) of 32.2 months versus 28.7 months for non-users (P < .001). Patients with stage III disease had a greater survival benefit with statin use (31.7 versus 25.9 months, P < .001). The statin benefit applied to patients with serous (HR 0.69, 95% CI, 0.55-0.87, P = .002) and nonserous tumors (OR 0.33-0.82, P = .005).
Moderate-dose therapy was associated with a 40% reduction in the survival hazard (P < .0001) and high-dose therapy with a 33% reduction (P = .04). Patients on low-dose statin therapy had survival similar to that of nonusers.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More